CrushSCI.com
52.4平均天数
38中位天数
4最短天数
179最长天数
1532025发文量

Paper Review Records

全部论文审稿周期

21 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

4 天

Centanafadine (Simtriyo®): a first-in-class triple reuptake inhibitor approved for attention-deficit/hyperactivity disorder (ADHD)

作者
Longqin Hu展开收起
作者单位
1. Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, USA; 2. The Cancer Institute of New Jersey, New Brunswick, USA展开收起
PDF源文件 DOI 网页
56 天

Review of promising benzimidazole-based anticancer agents (2023-2026)

作者
Elena Y. Shumilova; Sergey V. Sysolyatin; Svetlana V. Strokova展开收起
作者单位
1. Institute for Problems of Chemical and Energetic Technologies, Siberian Branch of the Russian Academy of Sciences (IPCET SB RAS), Biysk, Russia展开收起
PDF源文件 DOI 网页
58 天

Design, synthesis, biological activity and computational simulation evaluation of pyrimidine-2-aminoacetamide derivatives as cholinesterase inhibitors

作者
Yi-Xuan Wang; Shi-Hao Qin; Qian Liu; Xue-Wei Zhou; Chao-Yue Zhang; Zheng-Yue Ma展开收起
作者单位
1. College of Pharmaceutical Sciences, Institute of Life Science and Green Development, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, State Key Laboratory of New Pharmaceutical Preparations and Excipients, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Hebei University, Baoding, China; 2. Technology Center of Shijiazhuang Customs District, Baoding, China展开收起
PDF源文件 DOI 网页
5 天

Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer

作者
Sumi Lee; Longqin Hu展开收起
作者单位
1. School of Pharmacy and Institute of New Drug Development, Jeonbuk National University, Jeonju, Republic of Korea; 2. Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, The State University of New Jersey, 160 Frelinghuy sen Road, Piscataway, Rutgers, USA; 3. The Cancer Institute of New Jersey, New Brunswick, USA展开收起
PDF源文件 DOI 网页
32 天

Dual-target carbonic anhydrase inhibitors in cancer therapy: progress, challenges, and opportunities

作者
Meizhen Luo; Yong Wang; Yinmei Xia; Qin-Min Wang; Jifa Zhang; Lianhai Shan展开收起
作者单位
1. School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China; 2. Department of Neurology, Laboratory of Neuro-system and Multimorbidity, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China展开收起
PDF源文件 DOI 网页
38 天

Enhancement of antitumor activity through structural optimization of 2-(Benzylamino)-thieno[2,3-d]pyrimidin-4(3H)-ones

作者
Nazariy Pokhodylo; Kostiantyn Levchenko; Nataliya Finiuk; Yuliia Kozak; Olha Klyuchivska; Rostyslav Stoika展开收起
作者单位
1. Ivan Franko National University of Lviv, Lviv, Ukraine; 2. Institute of Cell Biology, National Academy of Sciences of Ukraine, Lviv, Ukraine展开收起
PDF源文件 DOI 网页

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。